Mohammad AskarPublic working copy · medical review pending

Preservatives and the ocular surface · 112

Glaucoma drops: protect pressure control and the ocular surface

Assess symptoms, tear film, cornea and treatment use together before choosing a better tolerated regimen.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Preservatives are not required for every effective formulation. Reduce avoidable surface burden while checking that glaucoma remains controlled.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Connect tolerance with sustained treatment

Ocular surface disease (OSD) can cause discomfort, fluctuating vision and difficulty using glaucoma drops. Assess the surface alongside intraocular pressure (IOP), optic nerve and visual field; one good pressure reading does not describe the whole treatment burden. 1

A systematic review included 16 studies; 13 pressure studies involved 4201 patients followed for 15 days to 6 months. It found no clinically important pressure difference between the studied BAK-preserved and alternative/preservative-free formulations; this does not prove that every product or every long-term safety outcome is equivalent. 2

Short follow-up, heterogeneous formulations and high or unclear risk of bias limit the safety comparison. The original claim that preservatives are indispensable for penetration is too broad, as is the opposite promise that removing them will secure future surgical success. 1 2

02Separate preservative chemistry from experimental injury

Benzalkonium chloride (BAC/BAK) is a quaternary ammonium preservative. The lecture also names “Zitrimit”/cetrimide, thiomersal, alcohols and parabens; the exact first spelling remains unresolved. Preservative and active treatment are different roles: chlorhexidine used for Acanthamoeba keratitis cannot be equated with a preservative formulation or concentration. 1

The original 0.005–0.02% clinical range must be checked against the actual product. Cell and animal experiments support concentration- and exposure-dependent epithelial injury, barrier disruption, apoptosis and growth inhibition; a 1% experimental exposure is not evidence that standard use destroys every anterior segment. 1 6

Tear-film lipid disturbance and epithelial changes can contribute to symptoms. Karcher’s attribution, the exact direction of surface-tension change, chromatin condensation and Brewitt’s electron-microscopic epithelial bridges remain original mechanistic details requiring their primary reports; they are not interchangeable with clinical fluorescein punctate staining. 1

03Interpret tear, cell and nerve findings in context

Schirmer testing, tear breakup time (BUT), surface staining and examination of the lids and meibomian glands describe different aspects of the surface. The original Martone and preserved-travoprost goblet-cell observations need their exact comparator, formulation and baseline disease; neither one result nor a group association establishes total loss of the mucin layer. 1

Animal nerve injury and human sensory testing answer different questions. The original day 3/day 6 nerve-loss and 1–2-minute timolol-sensitivity claims remain incompletely traced; an immediate fall in sensitivity is not proof of irreversible anatomical denervation. Confocal microscopy can document subbasal morphology, but does not isolate preservative causation from drug, exposure or disease. 1 6

A small human comparison of 20 healthy volunteers found more short-term tear-film and barrier disturbance with preserved timolol. This supports attention to tolerability, but a healthy short-term experimental population cannot quantify chronic nerve loss, glaucoma progression or surgical failure in treated patients. 7

04Assess inflammation and scarring without deterministic forecasts

Matrix metalloproteinase 9 (MMP9) is a nonspecific inflammatory marker. The original 50% versus 17% comparison lacks a verified cohort and assay threshold; a positive result does not by itself prove BAK injury, and a negative test does not exclude every surface disorder. 1

Chronic conjunctival inflammation can involve macrophages, lymphocytes and fibrotic repair with fibroblast-to-myofibroblast change and extracellular matrix deposition. The Broadway attribution and approximately 90% primary-surgery success figure need the original design and success definition; prior medication exposure, disease severity and surgical selection are confounded. Bleb failure is not predetermined by preservative exposure alone. 1

Progressive cicatrising conjunctivitis may represent drug-associated pseudopemphigoid, but mucous membrane pemphigoid and other causes must be considered. Document fornix shortening and scarring and arrange specialist assessment rather than assigning every case to BAK or promising reversibility after a switch. 1

05Explore adherence and diagnose the actual surface disorder

Ask about burning, missed doses, refill access, technique, number of bottles and daily dosing burden without blame. The original adherence 89→63%, one-year persistence 33–39%, and self-report 100% versus measured approximately 70% figures have unmatched populations and methods; they are not individual predictions or proof that OSD alone caused nonadherence. 1

A possible cycle connects irritation, poorer use, inadequate pressure control and more treatment, but progression has several determinants. Improve technique and access as well as tolerability, then reassess pressure and the nerve instead of assuming that a surface intervention alone will prevent loss. 1

For dry eye, symptom assessment with an objective homeostasis marker helps establish the diagnosis; the historical TFOS DEWS II approach uses breakup time, osmolarity or staining. BUT <10 seconds is an original teaching threshold dependent on the method. Meibomian dysfunction helps subtype assessment, and MMP9 is not compulsory for every diagnosis; neurotrophic loss may reduce symptoms despite significant damage. The unnamed 2024 consensus is not independently identified. 1 3

Redness alone does not distinguish inflammation from pharmacological vasodilation. Netarsudil-containing treatment can produce hyperaemia; the EMA identifies Roclanda as netarsudil plus latanoprost, whereas the original name “Rocklander” remains unverified. Pain, reduced vision, epithelial defects and other findings still require assessment rather than dismissing all redness as harmless. 1 5

06Reduce avoidable burden and monitor both outcomes

Consider a suitable preservative-free pressure formulation or a lower bottle burden when intolerance or surface disease warrants it; assess the active drug, contraindications, availability and ability to use the dispenser. Check IOP after changes rather than ordering an immediate identical switch for every patient. 1

Preservative-free lubricants and appropriate lid care can help selected tear-film or meibomian problems. Oral doxycycline is an individual option, not obligatory for every MGD finding; systemic adverse effects and contraindications matter. Short topical steroid courses need an indication, infection assessment and pressure monitoring. 1

Ciclosporin A is not automatically on-label for all severe OSD. The inspected EMA Ikervis indication is severe keratitis in adults with dry eye that has not improved with tear substitutes; confirm the local product and patient. The original promises of restored goblet cells, nerve density and sensitivity require their own outcome studies and are not guaranteed for glaucoma patients. 1 4

Selected SLT or surgery may reduce drop dependence when the glaucoma indication and patient preferences support it. Neither is a universal early substitute or a guarantee that damaged surface tissue recovers. Review symptoms, signs, practical use, IOP and progression together and agree the next follow-up. 1

Reduce avoidable burden and monitor both outcomes
ParameterOriginal finding and limitPractical consequence
BAC concentration0.005–0.02%; dose/exposure-dependent experimental injuryCheck actual formulation; no inevitable destruction
Pressure lowering16 studies; 4201 in 13 pressure studiesNo essential preservative for every effective formulation; long-term safety uncertain
NeurotoxicityOriginal 1–2-minute sensory change not irreversible nerve lossSeparate sensory, confocal and animal outcomes
Surgical failureFibroblast → myofibroblast; fibrosis modelExposure association does not determine bleb failure
Netarsudil / original RocklanderHyperaemia can reflect vasodilation; original brand unresolvedRedness ≠ proven inflammation; assess other signs
MMP9Original 50% versus 17% not source-matchedNonspecific marker; no sole or compulsory diagnosis
Ciclosporin AOriginal nerve/sensitivity benefit not guaranteedIkervis label requires adult severe dry-eye keratitis despite tear substitutes
What are the main learning points?

Preservatives are not required for every effective formulation. Reduce avoidable surface burden while checking that glaucoma remains controlled.

When is assessment urgent?

New visual loss, marked pain, a corneal defect or progressive conjunctival scarring needs prompt eye assessment. Do not stop pressure treatment without a replacement plan.

References and access status

  1. 1
    Immutable original export; preservative/ocular-surface teaching

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  2. 2
    Hedengran et al. preserved versus alternative/PF glaucoma drops: systematic review 2020

    Complete official NCBI abstract read14November2026; full review, individual trials and supplements unread.

  3. 3
    TFOS DEWS II Diagnostic Methodology2017

    Selected indexed sections6/8 on tests and homeostasis read14November2026; historical report, not full current DEWSIII appraisal or original unnamed2024 consensus.

  4. 4
    EMA Ikervis product information

    Indexed official indication4.1 and selected4.2 plus EPAR summary inspected14November2026; not whole label or all safety sections.

  5. 5
    EMA Roclanda product information

    Indexed active-ingredient and hyperaemia4.8 passages inspected14November2026; not full label, and original Rocklander identity unresolved.

  6. 6
    Sarkar et al. Corneal neurotoxicity due to topical BAK2012

    Selected indexed primary abstract methods/results and introduction read14November2026; mouse/cell work, not full paper, human nerve-loss estimate or original day3/day6 verification.

  7. 7
    Ishibashi et al. short-term preserved/unpreserved timolol2003

    Indexed primary purpose/methods/conclusion read14November2026;20 healthy volunteers; complete results/report unread. No irreversible-denervation inference.